Clinical Trial

Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A\*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
Protocol Amendment History 9 amendments
This ClinicalTrials.gov record has been amended 9 times since 2023-10-05; most recent amendment 2026-02-25.
Status change: Not Yet Recruiting → Recruiting 2025-03-12
Trial Details
NCT Number NCT06070012
Lead Sponsor Diwakar Davar
Collaborators: Immunocore Ltd
Conditions Uveal Melanoma
Enrollment 44 participants
Start Date 2025-08-18
Primary Completion 2028-09-30 (estimated)
Study Completion 2030-09-30 (estimated)
Updated on ClinicalTrials.gov 2026-02-27